Janus Henderson Group
LXRX icon

Janus Henderson Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Janus Henderson Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,470
Closed -$32K – 2581
2023
Q3 		$32K Buy
29,470
+335
+1% +$588 ﹤0.01% 2555
2023
Q2 		$66.9K Buy
29,135
+505
+2% +$1.34K ﹤0.01% 2582
2023
Q1 		$69.4K Buy
28,630
+17,269
+152% +$39.6K ﹤0.01% 2642
2022
Q4 		$21.6K Hold
11,361
– – ﹤0.01% 2452
2022
Q3 		$27K Hold
11,361
– – ﹤0.01% 2155
2022
Q2 		$21K Sell
11,361
-454
-4% -$866 ﹤0.01% 2587
2022
Q1 		$25K Buy
11,815
+29
+0.2% +$80 ﹤0.01% 2633
2021
Q4 		$46K Buy
+11,786
New +$57.2K ﹤0.01% 2541

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Janus Henderson Group's LXRX Position: Q4 2023 in Review

Janus Henderson Group sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2023, closing a stake of 29,470 shares — an estimated $32K sold.

Janus Henderson Group first reported a position in LXRX in Q4 2021 and held it in 8 quarters. The position peaked at $69.4K in Q1 2023. 106 funds tracked by Wall St. Rank hold LXRX as of Q4 2023.

  • Janus Henderson Group reported no remaining Lexicon Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Janus Henderson Group sold 29,470 Lexicon Pharmaceuticals shares in Q4 2023, an estimated $32K.
  • Janus Henderson Group first reported a position in Lexicon Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Janus Henderson Group's Lexicon Pharmaceuticals position peaked at $69.4K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2023.

Based on Janus Henderson Group's 13F filing for Q4 2023, filed 14 Feb 2024.